Cognitive dysfunction associated with cellular immunotherapy for cancer
Open Access
- 19 March 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (Supplement) , 13-24
Abstract
Immunotherapies engage the individual’s immune system to fight both hematologic and solid malignancies and have led to durable clinical responses for many patients. A subset of immunotherapies, including T cell engagers (TCEs) and chimeric antigen receptor T-cell therapies (CAR-T), use T cell mediated mechanisms to induce cancer cell death. These therapies can be very effective against the cancer while also causing significant systemic and neurologic toxicity, including cognitive dysfunction. Here, we provide a review on the existing and emerging literature describing the acute, subacute, and potential long-term effects of CAR-T cells and other T-cell-engaging therapies on cognition. While the acute effects on cognition, including immune effector cell-associated neurotoxicity syndrome are becoming better characterized, there is mixed data on the long-term subjective and objective cognitive outcomes after T-cell-based immunotherapies. Further research is needed, especially as these promising and effective therapies become more commonly used for both hematologic and solid malignancies.Keywords
This publication has 94 references indexed in Scilit:
- Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain MetastasesClinical Lung Cancer, 2025
- Parkinsonism Following Chimeric Antigen Receptor T Cell TherapyJAMA Neurology, 2024
- Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?HemaSphere, 2024
- Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative StudyOncology and Therapy, 2021
- Rethinking mechanisms of neurotoxicity with BCMA directed therapyCritical Reviews in Oncology/Hematology, 2021
- Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell TherapyJAMA Neurology, 2020
- Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgmentQuality of Life Research, 2014
- Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trialsCancer, 2012